deregulation may contribute to the development of solid tumours and haematological malignancies.
MiR-382-5p has been found to be upregulated in patients with myeloid neoplasms but its role in normal hematopoiesis is still unknown. Here we demonstrated that miR-382-5p overexpression in CD34+ hematopoietic stem/progenitor cells leads to a significant decrease of megakaryocyte precursors coupled to increase of granulocyte ones. Furthermore, by means of a computational analysis using different prediction algorithms, we identified several putative mRNA targets of miR-382-5p that are downregulated upon miRNA overexpression (i.e. FLI1, GATA2, MAF, MXD1, RUNX1 and SGK1). Among these, we validated MXD1 as real target of miR-382-5p by luciferase reporter assay. Finally, we showed that MXD1 knockdown mimics the effects of miR-382-5p overexpression on granulocyte and megakaryocyte differentiation of CD34+ cells.
Overall, our results demonstrated that miR-382-5p expression favours the expansion of granulocyte lineage and impairs megakaryocyte commitment through MXD1 downregulation. Therefore, our data showed for the first time that the miR-382-5p/MXD1 axis plays a critical role in myelopoiesis by affecting the lineage choice of CD34+ hematopoietic stem/progenitor cells.
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INTRODUCTION
MicroRNAs (miRNAs) are a large class of small noncoding RNAs that act as posttranscriptional regulators of gene expression (1) . miRNAs simultaneously modulate the expression of several targets by binding to the 3'-untraslated region (3'-UTR) of the mRNAs, resulting in mRNA destabilization and/or translational inhibition (2) .
In the last decade, growing evidence has unravelled the role of miRNAs as key regulators of stem cell fate by modulating essential processes like self-renewal, proliferation and differentiation. In particular, the combinatorial expression of miRNAs can precisely characterize specific cell types and regulate different phases of differentiation (3, 4) . Moreover, recent advancements in computational and molecular biology have highlighted the existence of regulatory networks where miRNAs modulate the expression of transcription factors and transcription factors regulate miRNA levels to promote or maintain some important cell functions (1) . On the other side, miRNA expression deregulation may contribute to the development of different human diseases, including cancer (5) .
In this study, we focused our attention on miR-382-5p, which resulted to be deregulated in several solid tumours and hematologic neoplasms (6) (7) (8) (9) . In particular, miR-382-5p upregulation has been reported in Acute Promyelocytic Myeloid Leukemia (AML-M3) (10, 11) and in Primary Myelofibrosis (PMF) patients (12).
Despite an abnormal expression level of miR-382-5p has been described in these hematological malignancies, its role in normal hematopoiesis has not been described so far. Therefore, in order to characterize the function of miR-382-5p in myeloid development, we evaluated the effects of its overexpression on the commitment of human CD34+ hematopoietic stem/progenitor cells (HSPCs). Interestingly, we identified MAX dimerization protein 1 (MXD1) as a target of miR-382-5p, and This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. demonstrated that miR-382-5p favours granulocyte lineage at the expense of megakaryocyte one through MXD1 downregulation.
MATERIALS AND METHODS
Human CD34+ cells purification
Umbilical cord blood (CB) samples were collected after normal deliveries, according to the institutional guidelines for discarded material (Clearance of Ethical Commitee for Human experimentation of Modena: Secretary office Saverio Santachiara, santachiara.saverio@policlinico.mo.it, approval date: 18.01.2005; approval file number # 793/CE). CB CD34+ cells were purified as previously described (13) . After immunomagnetic separation, CD34+ cells were seeded in 24-well plates at 5 × 10 5 /ml in Iscove's modified Dulbecco's medium (IMDM) (Euroclone SPA, Milan, Italy) containing 20% human serum (Bio-Whittaker, Walkersville, MD, USA), stem cell factor (SCF) (50 ng/ml), FLT3-ligand (FLT3L) (50 ng/ml), thrombopoietin (TPO) (20 ng/ml), interleukin-6 (IL6) (10 ng/ml), and interleukin-3 (IL3) (10 ng/ml) (all from Miltenyi Biotec, Auburn, CA, USA).
Electroporation of CD34+ cells
Human CD34+ cells were transfected by using the 4D-Nucleofector System (Lonza Group Ltd, Basel, Switzerland) as previously reported (12). Briefly, after 24 hours of incubation in the cell-culture condition described above, CD34+ cells were This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. the program DS112. After each transfection, CD34+ cells were transferred into prewarmed fresh medium in 24-well plates (Euroclone) and maintained in the same culture conditions as described above.
For small interfering RNAs (siRNAs) transfection, each sample was electroporated 3 times, once every 24 hours, with 3 µg of a mix of 3 Silencer Select siRNA targeting human MXD1 (supplemental Table 1 ) (Life Technologies). As previously described, CD34+ cells were nucleofected 24 hours after immunomagnetic purification, by using the P3 Primary Cell Solution (Lonza) and the electroporation protocol DS112. To exclude nonspecific effects caused by interfering RNA (RNAi) nucleofection, a sample transfected with a non-targeting siRNA negative control (ss-NegCTR;
Silencer Select Negative Control #2 siRNA; Life Technologies) was included.
Cells were analyzed 24 and 48 hours after the last nucleofection for both cell viability and miR-382-5p and/or MXD1 expression.
Viability measurement was assessed by trypan blue exclusion assay 24 hours after the last nucleofection (14) . In a Neubauer chamber, at least 100 cells were microscopically analyzed in duplicate for viability. The mean percentage of living cells of the two analyses was calculated.
CD34+ cell-culture conditions, morphological and immunophenotypic analysis
CD34+ cells were plated (5×10 5 /mL) in IMDM with the addition of 20% BIT 9500 serum substitute (bovine serum albumin, insulin, and transferrin; StemCell Technologies) 24 hours after the last nucleofection, in order to set up a multilineage cell culture (SCF, 50 ng/mL; FLT3L, 50 ng/mL; TPO, 20 ng/mL; IL-3, 10 ng/mL; IL-6, 10 ng/mL; all cytokines from Miltenyi), megakaryocyte (MK) unilineage culture (TPO, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 100 ng/mL), and granulocyte (GN) unilineage culture (SCF, 10 ng/mL; G-CSF, 25 ng/mL) (13 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. CA, USA). After a first phase of expansion, at 24 hours of culture (day 0) cells were seeded (5 × 105/ml) in IMDM added with 20% BIT (StemCell Technologies) in order to set up erythrocyte (EPO 0,4U/ml, SCF 10 ng/ml), megakaryocyte (TPO 100 ng/ml), granulocyte (GCSF 25 ng/ml, SCF 10 ng/ml) and monocyte (MCSF 100 ng/ml, SCF 20 ng/ml, IL6 20 ng/ml and Flt3L 50 ng/ml) unilineage cultures (13 
Methylcellulose and collagen clonogenic assays
Two different clonogenic assays were performed at 24 hours after the last nucleofection. The methylcellulose assay was carried out by plating CD34+ cells in MethoCult TM H4434 Classic (StemCell Technologies Inc.; Vancouver), as previously described (15) . In addition, MK colony forming units (CFU-MK) were assayed in collagen-based medium, using a commercial MK assay detection kit (MegaCult-C;
StemCell Technologies Inc.) as previously reported (16) .
RNA purification and quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total cellular RNA, including small RNAs, was isolated from CD34+ cells using the miRNeasy mini RNA isolation kit (Qiagen, Hilden, Germany) following the manufacturer's recommendations. The purity and integrity of RNA samples were This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. determined by using disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) and the Agilent 2100 Bioanalyzer (Agilent Technologies; Waldbrunn, Germany).
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Wilmington, DE) was used to evaluate the RNA sample concentration, while 260/280 nm and 260/230 nm ratios were used to assess the purity of RNA.
cDNA was reverse-transcribed from total RNA (100 ng per sample) using the High- (17) . Gene expression relative quantification (RQ) was achieved using the comparative cycle threshold (CT) method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene. The ss-NegCTR sample was considered as the calibrator, the RQ value was expressed as 2−ΔΔCT.
For miRNA cDNA synthesis, 5 ng of total RNA was reverse-transcribed using the Taqman microRNA Reverse Transcription Kit and specific primers included in TaqMan MicroRNA assays. qRT-PCR was performed using TaqMan MicroRNA assays (Life Technologies) as described above and U6 snRNA as a housekeeping control.
Luciferase reporter assays
Predicted target sites of miR-382-5p were cloned into the Pme1 and XbaI sites of This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Table 2 In order to analyze the data, three levels of normalization were performed as previously described: firstly, firefly luciferase activity was normalized to that of Renilla luciferase as the internal control for nucleofection efficiency; secondly, the data were normalized to the effect of the miRNA mimic on the empty vector control reporter; lastly, the luminescence signals were normalized to the effect of the m-NegCTR on the corresponding miRNA binding site-containing construct (12). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
Statistical analysis
The statistics used for data analysis in overexpression/silencing experiments and luciferase reporter assays were based on 2-tailed Student t tests for averages comparison in paired samples. Data were analyzed by using Microsoft Excel This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
RESULTS
MiR-382-5p overexpression in CD34+ cells
In order to study the role of miR-382-5p in HSPC commitment, miR-382-5p was overexpressed in CD34+ cells. By means of qRT-PCR, we confirmed that the miRNA expression level was upregulated upon miR-382-5p mimic transfection at 24 and 48
hours (RQ ± SEM, 1677 ± 383, P < .05 and 625 ± 85 P < .01, respectively) after the last nucleofection ( Figure 1A ). Trypan blue exclusion assay showed that cell viability was about 90% in both m-NegCTR and miR-382-5p samples ( Figure S1A ). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Consistently with previous results, methylcellulose assay highlighted a remarkable increase in the percentage of granulocyte colony forming unit (CFU-G), whereas monocyte (CFU-M), erythroid (Burst-Forming Units (BFU-E) and CFU-E) and granulo-monocyte (CFU-GM) colonies were not significantly affected ( Figure 3A) .
Furthermore, the collagen-based assay that supports the growth of MK progenitors in vitro showed that miR-382-5p overexpression causes a significant decrease in the CFU-MK percentage coupled with a significant increase of non-MK colonies ( Figure   3B ). This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
MiR-382-5p target prediction and validation by luciferase reporter assays
In order to identify the molecular targets through which miR-382-5p modulates the MK and GN commitment in CD34+ HSPCs, several prediction algorithms (i.e.
TargetScan, microRNA.org, PITA, etc.) were used. In a combinational analysis with these different tools we found out several predicted targets of miR-382-5p, which contain a putative binding site for miR-382-5p in their 3'-UTR. Next, we selected those genes known to be involved in MK and GN differentiation (i.e. FLI1, GATA2, MAF, MXD1, RUNX1, and SGK1) ( Table 1 ) (18-22).
First, we assessed whether miR-382-5p overexpression in CD34+ HSPCs led to the down-regulation of putative target expression by means of qRT-PCR. As shown in Figure 4A , all mRNAs were downregulated in miR-382-5p-overexpressing cells at 24 hours after the last nucleofection.
Finally, to confirm whether the downregulated mRNAs are real targets of miR-382-5p, we validated every putative miRNA-mRNA interaction by means of luciferase reporter assay. To this end, the predicted miRNA binding sites were cloned into the 3'-UTR of the Dual Luciferase pmirGLO vector and transiently transfected in K562 cells.
Luciferase activity was measured in the presence of miR-382-5p mimic or mNegCTR and normalized using Renilla activity. As shown in Figure 4B , miR-382-5p
overexpression significantly inhibited the luciferase activity in the sample transfected with the wild type miRNA binding site on MXD1 3'-UTR; conversely, the luciferase This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. reporter assay results, Western blot analysis showed a marked reduction of MXD1 protein level upon miR-382-5p overexpression ( Figure 4C ).
MXD1 silencing in CD34+ cells
To better characterize the role of miR-382-5p/MXD1 axis in myelopoiesis, we investigated whether MXD1 silencing could reproduce the effects mediated by miR-382-5p overexpression on GN and MK differentiation. Therefore, CD34+ cells were transfected with a mixture of three Silencer Select siRNAs targeting MXD1 mRNA (supplemental Table 1 ) and with a non-targeting siRNA as a negative control (ss- This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. MiR-382-5p overexpression has been described in some hematological malignancies, such as PMF (12) and Acute Myeloid Leukemia (AML) (10, 11), even if its role in normal hematopoiesis was still unknown.
Here we showed for the first time that miR-382-5p plays a critical role in hematopoiesis by influencing the lineage choice of CD34+ cells. In particular, we demonstrated that miR-382-5p supports the expansion of granulocyte lineage whereas negatively interferes with megakaryocyte commitment, as demonstrated by a significant increase of granulocyte precursors coupled to decrease of megakaryocyte ones in miR-382-5p-overexpressing cells (Figure 1-3) .
Next, in order to identify the molecular targets by which miR-382-5p regulates HSPC fate, we found by a prediction analysis several putative targets known to be involved in MK and GN differentiation (i.e. FLI1, GATA2, MAF, MXD1, RUNX1, and SGK1) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. megakaryocyte precursors coupled to increase of granulocyte ones (Figure 5 and 6 ).
According to our results, the increased expression of MXD1 has been previously reported also in megakaryocytes obtained in vitro from human CD34+ cells (21).
Therefore, the MXD1 expression in CD34+ cells seems to be essential for megakaryocyte differentiation; in fact, the MK transcription factors GATA2, FLI1 and RUNX1 were significantly decreased after MXD1 silencing (Figure 7 ) (18),
suggesting that the expression of these genes could be regulated by MXD1 in a direct or indirect way. For instance, the downregulation of GATA2, FLI1 and RUNX1 might be mediated by the MXD1-driven inhibition of a transcriptional repressor (i.e. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Norfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., Pietra, D., Salmoiraghi, S., This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Bianchi, E., Bulgarelli, J., Ruberti, S., Rontauroli, S., Sacchi, G., Norfo, R., Pennucci, V., Zini, R., Salati, S., Prudente, Z., Ferrari, S., and Manfredini, R. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Values are reported as mean ± SEM; *, P < .05 versus mutated miRNA binding site.
BCL6) (25)
Results come from three independent experiments performed in duplicate.
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